Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026
Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026
Company Drug

Innovent Biologics & Sanegene Bio USA Report First‑in‑Human Success for IBI3016 siRNA Hypertension Therapy

Fineline Cube Nov 11, 2025

Innovent Biologics, Inc. (HKG: 1801) and Sanegene Bio USA Inc. announced today the first‑in‑human (FIH)...

Company Drug

Hangzhou Bio‑Sincerity Secures NMPA Approval for BIOS‑0625 Tablet – First‑in‑Class Ulcerative Colitis Therapy

Fineline Cube Nov 11, 2025

Hangzhou Bio‑Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS‑0625 tablet, a Class 1 small‑molecule...

Company Deals

CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines

Fineline Cube Nov 11, 2025

CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co.,...

Company Deals

Eisai China and Beckman Coulter Launch Alzheimer’s Blood‑Test Collaboration in Mainland China

Fineline Cube Nov 10, 2025

Eisai China Holdings (TYO: 4523) and Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. today signed...

Company Drug

Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial

Fineline Cube Nov 10, 2025

Gilead Sciences Inc. (NASDAQ: GILD) today disclosed that the Phase III ASCENT‑07 study, which compared Trodelvy...

Company Deals

Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance

Fineline Cube Nov 10, 2025

Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...

Company Deals

SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases

Fineline Cube Nov 10, 2025

SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and...

Company Deals

DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform

Fineline Cube Nov 10, 2025

Nantong DeliNova Therapeutics Co., Ltd. announced today the successful closing of a seed‑stage financing round...

Company Deals

Organon Acquires JADA System from Laborie for USD 465 Million

Fineline Cube Nov 10, 2025

Organon Inc. (NYSE: OGN) announced today that it has entered into an agreement with Laborie...

Company Deals Digital

HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration

Fineline Cube Nov 10, 2025

HBM Holdings Limited (HKG: 2142) and Evinova, an independent health‑tech arm of the AstraZeneca Group,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Announces HRS‑2430 Injection Approval for Clinical Trials

Fineline Cube Nov 10, 2025

China‑listed Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous...

Others

National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)

Fineline Cube Nov 10, 2025

The National Health Commission (NHC) announced on 7 November 2025 a “Negative Behavior List for Medical Staff...

Company Deals

Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal

Fineline Cube Nov 10, 2025

Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...

Company Deals

Aureka Biotechnologies Closes Multi‑Million‑Dollar Series A – Generative Antibody Platform Gains 5Y Capital & Qiming Backing

Fineline Cube Nov 10, 2025

Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of...

Company Deals

Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion

Fineline Cube Nov 8, 2025

China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s...

Company Deals

Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030

Fineline Cube Nov 8, 2025

During the 8th China International Import Expo (CIIE), the Shanghai Medical Association (SMA) and Boehringer Ingelheim...

Company Deals Hospital

Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative

Fineline Cube Nov 8, 2025

Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...

Company

Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows

Fineline Cube Nov 8, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third‑quarter 2025 financial results, reporting total...

Company Deals

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Fineline Cube Nov 8, 2025

In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...

Policy / Regulatory

NHSA Pilot AI Review Accelerates Full‑Process Medical Insurance Assessment in 7 Chinese Provinces

Fineline Cube Nov 8, 2025

The National Healthcare Security Administration (NHSA) has announced a three‑phase, AI‑powered review pilot covering Beijing,...

Posts pagination

1 … 44 45 46 … 628

Recent updates

  • Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy
  • HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline
  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.